OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

OnKure Therapeutics, Inc. (NASDAQ:OKUR) has been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $32.3333.

Several research firms have recently weighed in on OKUR. Zacks Research cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Wall Street Zen raised shares of OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of OnKure Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of OnKure Therapeutics in a research note on Tuesday, August 26th.

OnKure Therapeutics Price Performance

OKUR stock opened at $2.86 on Thursday. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $15.89. The stock has a market cap of $38.75 million, a price-to-earnings ratio of -0.60 and a beta of 0.46. The company has a 50 day simple moving average of $2.93 and a 200 day simple moving average of $2.62.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.11. On average, equities research analysts anticipate that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC bought a new stake in OnKure Therapeutics during the first quarter worth $43,000. XTX Topco Ltd purchased a new position in OnKure Therapeutics during the 2nd quarter worth $25,000. Bailard Inc. purchased a new position in OnKure Therapeutics during the 2nd quarter worth $34,000. Rangeley Capital LLC bought a new stake in shares of OnKure Therapeutics in the 2nd quarter worth $71,000. Finally, GSA Capital Partners LLP grew its position in OnKure Therapeutics by 172.1% in the 3rd quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after purchasing an additional 37,459 shares in the last quarter. 90.98% of the stock is owned by institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.